McAndrews

About

  • The Orange Book blog team are a group of attorneys with McAndrews, Held and Malloy, which is a full-service IP firm representing both brands and generics in various aspects of IP law. This blog does not provide legal advice. If you are seeking legal advice, please contact the author directly.

Disclaimer

  • Orange Book Blog is published for informational purposes only; it contains no legal advice whatsoever. Publication of Orange Book Blog does not create an attorney-client relationship. Orange Book Blog is not edited by McAndrews, Held & Malloy, Ltd. ("MHM") or its clients. The views expressed are solely those of the authors, and may not reflect the views of MHM or its clients. No part of Orange Book Blog--whether information, commentary, or other--may be attributed to MHM or its clients. MHM represents many companies in the pharmaceutical and biotechnology industries, and therefore Orange Book Blog may occasionally report on news that relates to MHM clients. Orange Book Blog will always strive to be unbiased. All information on Orange Book Blog should be double-checked for its accuracy and current applicability.

« Apotex Sues FDA to Recover 180-Day Exclusivity on Generic Plavix | Main | Barr and Caraco Win Summary Judgment that Ortho-McNeil's Formulation Patent on Ultracet is Invalid »

April 28, 2008

WBR "PharmaBiotech IP Summit," Philadelphia, May 28-30

Worldwide Business Research will be holding a conference entitled "PharmaBiotech IP Summit," May 28-30 at the Ritz-Carlton in Philadelphia.

According to WBR, "the event balances the challenges of IP protection, enforcement and management, providing both strategic and actionable insights through case studies and interactive session formats."

The conference will bring together over 35 speakers from the pharmaceutical and biotechnology industries, who will focus on protecting critical patents while driving sustainable growth through IP-driven business strategies.  They will address how patent reform legislation will impact IP practitioners in these industries.  In addition, they will tackle key issues such as strategic patent portfolio management, IP lifecycle extension and IP commercialization.

The conference begins with a "Patent Enforcement and Protection Master Class," on May 28.  The main conference, May 29-30, includes the following panel presentations:

  • "Aligning IP Strategy and the Business -- Becoming a Resource Not a Roadblock," with Scott Brown, VP, General Counsel, Head of NIBR Patents, Novartis; Guy Donatiello, VP IP, Endo Pharmaceuticals; and Karen F. Clark, Assoc. General Counsel, Global Health, Well Being and Beauty Care, Procter & Gamble Co.
  • "Patent Reform, Resolutions and Additional Rulings -- Interpretations, Impacts and Strategies for the Challenge Ahead," with Robert Hrubiec, VP IP and Chief Patent Counsel, Cephalon; Gary Creason, VP IP, Aveo Pharmaceuticals; and John T. Li, Patents, Head, Biology and Biologics, Novartis
  • "Biosimilars and Follow-on Biologics -- Preparing for the Road Ahead," with James Kelley, Assoc. General Counsel, Eli Lilly & Co.; John M. Engel, Managing Partner, Engel & Novitt, LLP; and Bradford J. Badke, Partner, Ropes & Gray LLP
  • "Ensuring Protection and Enforcement Post-KSR," with James Gould, Legal Director, Global Patent Litigation, Schering-Plough; Kathleen Fonda, Legal Advisor, Office of Patent Legal Administration, USPTO; and Cindy Clay, Sr. Counsel, IP, Global Personal Health Care and Pharmaceuticals, Procter & Gamble Co.

Orange Book Blog readers can receive a 15% discount on registration with Booking Code WUS_XZ206EN.

For more information or to register, please visit the conference website.

Posted by in Conferences |

Comments

The comments to this entry are closed.